April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification
Author Affiliations & Notes
  • Michelle Abou-Jaoude
    Herbert Wertheim College of Medicine at Florida International University, Miami, FL
  • William Trattler
    Center for Excellence in Eye Care, Miami, FL
  • Carlos Buznego
    Center for Excellence in Eye Care, Miami, FL
  • John Hovanesian
    Harvard Eye Group, San Clemente, CA
  • Bonnie Henderson
    Ophthalmic Consultants of Boston, Boston, MA
  • Footnotes
    Commercial Relationships Michelle Abou-Jaoude, None; William Trattler, Allergan (C), AMO (C), AMO (F), AMO (R), Baush and Lomb (C), Baush and Lomb (F), Baush and Lomb (R), Lensar (C); Carlos Buznego, None; John Hovanesian, None; Bonnie Henderson, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2542. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michelle Abou-Jaoude, William Trattler, Carlos Buznego, John Hovanesian, Bonnie Henderson; Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2542.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The study was a prospective, multicenter comparative trial evaluating the effectiveness of Loteprednol 0.5% vs. Prednisilone Acetate 1% for patients undergoing cataract surgery.

Methods: The study was conducted as a prospective, masked evaluation of 73 cataract surgery patients receiving either Loteprednol 0.5% or brand-name Pred Forte (Prednisolone Acetate 1%). Patients were included if they completed at least one follow-up visit. The patients were prescribed either loteprednol or prednisilone acetate, along with brand name bromfenac BID and besivance 0.6% BID starting 3 days before surgery. The topical steroid and a topical NSAID were continued for 4 weeks post-Op. Besifloxacin was continued for 10 days post-Op. Outcomes measured included CCT, UCVA, BCVA, MOCT, AC scores, and IOP at 1 day, 1 week, and 1 month postoperatively.

Results: At baseline 36 subjects were enrolled in Group A, 33% male, average age of 69. 37 subjects were enrolled in Group B, 41% male, average age of 66. There were not significant differences between Group A and Group B in the change at one month from preop in MOCT (p=0.07), UCVA (p=0.35), BCVA (p=0.48), IOP (p=0.87), or CCT (p=0.08). At one day, one week and one month 8.3%, 16.7%, and 61% of subjects had 0 cells and 0 flare in Group A while 13%, 27.8%, and 72% of subjects had 0 cells and 0 flare in Group B.

Conclusions: Groups A and B were statistically comparable at baseline and in MOCT, UCVA, BCVA, IOP, and CCT at one month post-op from baseline. Group B had a higher percentage of eyes with 0% combined cells/flare. 100% of patients at one month in both groups had BCVAs of 20/30 or higher.

Keywords: 445 cataract • 487 corticosteroids • 743 treatment outcomes of cataract surgery  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×